Rationale and design of the IRON ‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy
AbstractAimsIron deficiency is common in heart failure with reduced ejection fraction (HFrEF). In patients with cardiac resynchronization therapy (CRT), it is associated with a diminished reverse remodelling response and poor functional improvement. The latter is partially related to a loss in contractile force at higher heart rates (negative force –frequency relationship).Methods and resultsThe effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy (IRON ‐CRT) trial is a multicentre, prospective, randomized, double‐blind controlled trial in HFrEF patients who experienced incomplete reverse remodelling (defined as a left ventricular ejection fraction below
This article includes also recently announced findings on the TRANSITION study which revealed that HFrEF therapy with ARNI might be safely initiated after an acute decompensated heart failure episode, including patients with heart failure de novo and ACEI/ARB na ïve, both hospitalised or shortly after discharge, in contrary to the PARADIGM-HF trial, where patients had to be administered a stable dose of an ACEI/ARB equivalent to enalapril 10 mg a day for at least 4 weeks before the screening.
Abstract BACKGROUND: The first European Cardiac Resynchronization Therapy (CRT) Survey, conducted in 2008-2009, showed considerable variations in guideline adherence and implantation practice. A second prospective survey (CRT Survey II) was then performed to describe contemporary clinical practice regarding CRT among 42 European countries. AIM: To compare the characteristics of French CRT recipients with the overall European population of CRT Survey II. METHODS: Demographic and procedural data from French centres recruiting all consecutive patients undergoing either de novo CRT implantation or an upgrade...
This study included 36 patients. At rest, AV intervals changed minimally with posture. With atrial pacing, AV interval immediately increased compared with sinus rhythm, with ARV slopes being 8.1 ±7.7, 8.8±13.4 and 6.8±6.5 milliseconds per beat per minute (ms/bpm) and ALV slopes being 8.2±7.7, 9.1±12.8, and 7.0±6.5 ms/bpm for supine, standing and sitting positions, respectively. As paced heart rate increased, ARV and ALV intervals increased more gradually with similar trends. Intervent ricular conduction times changed
CONCLUSIONS: Reactive ATP successfully and safely reduced AF burden, and was associated with a lower incidence of HF hospitalization in patients implanted with CRT devices. PMID: 31672258 [PubMed - as supplied by publisher]
This study investigated the clinical effect of the aCRT algorithm, especially in mildly wide QRS (120≤QRS
Heart failure (HF) is a complicated syndrome, and despite advances in medical and device-based therapies in the last three decades, the 5-year mortality of patients with HF remains around 50%.1 Increasingly, patients with HF are implanted with implantable cardioverter defibrillators or cardiac resynchronization therapy devices that possess the capability of measuring many diagnostic parameters.
An implantable neuromodulation device was approved for symptom improvement in patients with advanced heart failure who aren ’t eligible for cardiac resynchronization therapy. Heart failure is the fourth leading cause of death attributable to cardiovascular disease, affecting 5.7 million people in the United States.
Nearly one-third of heart failure (HF) patients do not respond to cardiac resynchronization therapy (CRT) despite having left bundle branch block (LBBB). The aim of the study was to investigate a novel method ...
This article provides a review of the aforementioned mechanisms of arrhythmogenesi s in heart failure; the role and impact of HF therapy such as cardiac resynchronization therapy (CRT), including the role, if any, of CRT-P and CRT-D in preventing VAs; the utility of both non-invasive parameters as well as multiple implant-based parameters for telemonitoring in HF; and the effect o f left ventricular assist device implantation on VAs.
Exercise training is a well-established therapy for heart failure (HF) patients recommended in the European Society of Cardiology (ESC) HF guidelines . The last Cochrane Library Review about “Exercise-based cardiac rehabilitation for adults with heart failure” underlined the important benefits of exercise-based rehabilitation that include a reduction in the risk of overall hospital admissions in the short term, as well as a potential improvement of all-cause mortality in the long te rm (>12 months follow up) .